Congress clears CDER reorganization aimed at deepening FDA therapeutic expertise

Congress has signed off on an FDA reorganization that is intended to allow drug reviewers to develop greater expertise in both the diseases that are being treated and the technologies underlying new medicines.

The changes will create more senior positions and is part of a broader attempt to enable more FDA staff to become thought-leaders in their therapeutic areas. ...